Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Pyridine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAPRT | Q6XQN6 | 4/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | FYN | P06241 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | APP | P05067 | 1/20 | 0.37 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.37 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
| ▸ | PLOD2 | O00469 | 1/20 | 0.34 |
| ▸ | PLOD3 | O60568 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyridine SCHEMBL10977701 | 0.97 | NAPRT (0.60) | NAPRTTSHRTDP1FFAR3LCK | |
| Pyridine SCHEMBL11125163 | 0.97 | NAPRT (0.60) | NAPRTTSHRTDP1FFAR3LCK | |
| Pyridine SCHEMBL179840 | 0.97 | NAPRT (0.60) | NAPRTTSHRTDP1FFAR3LCK | |
| Pyridine SCHEMBL8582033 | 0.94 | NAPRT (0.56) | NAPRTTSHRTDP1FFAR3LCK | |
| Pyridine SCHEMBL10380397 | 0.94 | NAPRT (0.56) | NAPRTTSHRTDP1FFAR3LCK | |
| Pyridine SCHEMBL153596 | 0.94 | NAPRT (0.56) | NAPRTTSHRTDP1FFAR3LCK | |
| Pyridine SCHEMBL9246176 | 0.94 | NAPRT (0.56) | NAPRTTSHRTDP1FFAR3LCK | |
| Pyridine SCHEMBL5844201 | 0.94 | NAPRT (0.56) | NAPRTTSHRTDP1FFAR3LCK | |
| Pyridine SCHEMBL5844202 | 0.94 | NAPRT (0.56) | NAPRTTSHRTDP1FFAR3LCK | |
| Pyridine SCHEMBL11225938 | 0.94 | NAPRT (0.56) | NAPRTTSHRTDP1FFAR3LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1327637-B1 | Process for the preparation of L-Ribose | UNIV GEORGIA RES FOUND (US) | 2005-09-14 | — | — | EP | claimed |
| US-6894159-B2 | Process for the preparation of 2′-fluoro-5-methyl-beta-L-arabino-furanosyluridine | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION (US) | 2005-05-17 | — | — | US | claimed |
| US-20030139593-A1 | Process for the preparation of 2'-fluoro-5-methyl-beta-L-arabino-furanosyluridine | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION INC. | 2003-07-24 | — | — | US | claimed |
| EP-1327637-A1 | Process for the preparation of L-Ribose | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2003-07-16 | — | — | EP | claimed |
| CN-1113892-C | Process for preparation of 2'-fluoro-5-methyl-beta-L-arabino-furanosyluridine | UNIV OF GEORGIA RES FOUNDATION (US) | 2003-07-09 | — | — | CN | claimed |
| EP-0998482-B1 | PROCESS FOR THE PREPARATION OF 2'-FLUORO-5-METHYL-BETA-L-ARABINOFURANOSYLURIDINE | UNIV GEORGIA RES FOUND (US) | 2003-04-02 | — | — | EP | claimed |
| US-6512107-B2 | Generating preferential uridine derivative | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION | 2003-01-28 | — | — | US | claimed |
| US-20020062018-A1 | PROCESS FOR THE PREPARATION OF 2'- FLUORO-5-METHYL-BETA-L-ARABINO- FURANOSYLURIDINE | GEORGIA, UNIVERSITY OF, RESEARCH FOUNDATION INC., THE | 2002-05-23 | — | — | US | claimed |
| EP-0998482-A1 | PROCESS FOR THE PREPARATION OF 2'-FLUORO-5-METHYL-$g(b) -L-ARABINOFURANOSYLURIDINE | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2000-05-10 | — | — | EP | claimed |
| WO-1999005157-A1 | PROCESS FOR PREPARATION OF 2'-FLUORO-5-METHYL-β -L-ARABINOFURANOSYLURIDINE | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (KR) | 1999-02-04 | — | — | WO | claimed |
| WO-1999005158-A1 | PROCESS FOR THE PREPARATION OF 2'-FLUORO-5-METHYL-β -L-ARABINOFURANOSYLURIDINE | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1999-02-04 | — | — | WO | claimed |
| CN-1206012-A | Process for preparation of 2'-fluoro-5-methyl-beta-L-arabino-furanosyluridine | TNE UNIVERSITY OF GEORGIA RESE (US) | 1999-01-27 | — | — | CN | claimed |
| US-20090131406-A1 | CROPWELLLINS AND SYNTHETIC DERIVATIVES THEREOF USED AS MEDICAMENTS | BAYER CROPSCIENCE AG (DE) | 2009-05-21 | — | — | US | disclosed |
| CN-101243092-A | Cripowellins and synthetic derivatives thereof used as medicaments | BAYER CROPSCIENCE AG (DE) | 2008-08-13 | — | — | CN | disclosed |
| EP-1283211-B1 | L-Nucleosides for the treatment of hepatitis B-virus and Epstein-barr virus | UNIV GEORGIA RES FOUND (US) | 2006-06-07 | — | — | EP | disclosed |
| EP-1327637-B1 | Process for the preparation of L-Ribose | UNIV GEORGIA RES FOUND (US) | 2005-09-14 | — | — | EP | disclosed |
| WO-1995020595-A1 | L-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B-VIRUS AND EPSTEIN-BAR VIRUS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1995-08-03 | — | — | WO | disclosed |
| US-5098922-A | Anticonvulsants | CIBA-GEIGY CORPORATION (US) | 1992-03-24 | — | — | US | disclosed |
| US-5089487-A | Hypotensive agents | BAYER AKTIENGESELLSCHAFT (DE) | 1992-02-18 | — | — | US | disclosed |
| US-5045556-A | Aralkyl-4H-1,2,4-triazole derivatives | CIBA-GEIGY CORPORATION (US) | 1991-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131406-A1 | CROPWELLLINS AND SYNTHETIC DERIVATIVES THEREOF USED AS MEDICAMENTS | COIL, CIAPIN1, MEN1 | NAPRT 1934/4885TSHR 4683/4885TDP1 2823/4885 |
| US-20030139593-A1 | Process for the preparation of 2'-fluoro-5-methyl-beta-L-arabino-furanosyluridine | FBL, UMPS, NSUN2 | NAPRT 1837/4885TSHR 4463/4885TDP1 2115/4885 |
| US-20020062018-A1 | PROCESS FOR THE PREPARATION OF 2'- FLUORO-5-METHYL-BETA-L-ARABINO- FURANOSYLURIDINE | FBL, UMPS, NSUN2 | NAPRT 1837/4885TSHR 4463/4885TDP1 2115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.